N-环丙基-3-溴-4-氟苯甲酰胺 | 639858-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-环丙基-3-溴-4-氟苯甲酰胺
• 英文名称: 3-bromo-N-cyclopropyl-4-fluorobenzamide
• CAS: 639858-63-2
• 化学式: C₁₀H₉BrFNO
• 分子量: 258.09
• InChiKey: JXLIVLFFWYPTJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Cyclopropyl 3-bromo-4-fluorobenzamide
Synonyms: 3-Bromo-N-cyclopropyl-4-fluorobenzamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Cyclopropyl 3-bromo-4-fluorobenzamide
CAS number: 639858-63-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9BrFNO
Molecular weight: 258.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-环丙基-3-溴-4-氟苯甲酰胺 在 盐酸 、 9-硼双环[3.3.1]壬烷 、 copper(ll) bromide 作用下， 以 四氢呋喃 、 丙酮 、 乙腈 为溶剂， 反应 9.0h， 生成 N-cyclopropyl-4-fluoro-3-{2-[2-(pyridin-2-ylamino)-thiazol-5-yl]-ethyl}-benzamide
  参考文献：
  名称：

  Discovery and Evaluation of N-Cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a Selective and Orally Efficacious Inhibitor of Vascular Endothelial Growth Factor Receptor-2

  摘要：

  Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)-amino) benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The enzyme kinetics associated with the VEGFR-2 inhibition of 14 (K-i=49 +/- 9 nM) confirmed that the aminothiazole-based analogues are competitive with ATP. Analogue 14 demonstrated excellent kinase selectivity, favorable pharmacokinetic properties in multiple species, and robust in vivo efficacy in human lung and colon carcinoma xenograft models.

  DOI：

  10.1021/jm060347y
• 作为产物：
  描述：

  3-溴-4-氟苯甲酸 、 环丙胺 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.5h， 以93.3%的产率得到N-环丙基-3-溴-4-氟苯甲酰胺
  参考文献：
  名称：

  [EN] 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES
  [FR] DÉRIVÉS DE 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-MÉTHYLBENZAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS DE RIPK2 POUR TRAITER PAR EXEMPLE DES MALADIES AUTO-IMMUNES

  摘要：

  本发明涉及Formula 1的化合物及其药用盐，其中α、β、R2、R3、R4、R5、R8、R9、X1、X6和X7在说明书中有定义。Formula 1的化合物是受体相互作用蛋白激酶2（RIPK2）抑制剂，用于治疗例如I型超敏反应、自身免疫疾病、炎症性疾病、癌症和非恶性增殖性疾病，例如过敏性鼻炎、哮喘、特应性皮炎、类风湿关节炎、多发性硬化、系统性红斑狼疮、红斑性肾炎、银屑病、免疫性血小板减少性紫癜、炎症性肠病、慢性阻塞性肺病、干燥综合征、强直性脊柱炎、Behcet病、移植物抗宿主病、天疱疮、特发性浆细胞淋巴结病、动脉粥样硬化、心肌梗死和血栓形成。本说明书披露了示例化合物的制备以及其药理学数据（例如107至208页；示例1至109；表1）。一个示例化合物是N-环丙基-2-氟-5-（1-（2-氟乙基）-3-（1-羟基-2-甲基异丙基）-2-氧代-2,3-二氢-1H-咪唑并[4,5-b]吡啶-6-基）-4-甲基苯甲酰胺（示例1）。

  公开号：

  WO2020198053A1

文献信息

• Heterocyclic inhibitors of kinases
  申请人：——

  公开号：US20040077696A1

  公开（公告）日：2004-04-22

  The present invention provides compounds of formula I 1 and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了公式I的化合物 1 以及药用可接受的盐。 公式I化合物抑制生长因子受体如VEGFR-2、FGFR-1的酪氨酸激酶活性，从而使其作为抗癌剂具有用途。公式I化合物还用于治疗其他通过生长因子受体作用的信号转导通路相关的疾病。
• [EN] PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 6-AMINO-7-DÉSAZA-PURINE, PROCÉDÉ POUR LES PRÉPARER ET LEUR UTILISATION COMME INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2014184069A1

  公开（公告）日：2014-11-20

  The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.

  本发明涉及调节蛋白激酶活性的6-氨基-7-去氮嘌呤衍生物，因此在治疗由失调的蛋白激酶活性引起的疾病中特别有用，尤其是RET家族激酶。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用含有这些化合物的药物组合物治疗疾病的方法。
• PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：NERVIANO MEDICAL SCIENCES S.R.L.

  公开号：US20160166575A1

  公开（公告）日：2016-06-16

  The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.

  本发明涉及6-氨基-7-去氮嘌呤衍生物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病，特别是RET家族激酶方面非常有用。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用含有这些化合物的药物组合物治疗疾病的方法。
• HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1513818B1

  公开（公告）日：2010-01-20
• HETEROCYCLIC INHIBITORS OF KINASES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1513818A2

  公开（公告）日：2005-03-16